Hemispherx Bio…

Hemispherx BioPharma (HEB) stock price, revenue and financials

View Company

$9.2 M

HEB Mkt cap, 04-Dec-2018

$38 K

Hemispherx BioPharma Revenue Q3, 2018
Hemispherx BioPharma Net income (Q3, 2018)-3.1 M
Hemispherx BioPharma EBIT (Q3, 2018)-3 M
Hemispherx BioPharma Cash, 30-Sep-20184.1 M

Hemispherx BioPharma Income Statement

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

150.0k197.0k133.0k92.0k437.0k

Revenue growth, %

31%(32%)(31%)

R&D expense

8.4m9.0m8.0m5.1m4.1m

General and administrative expense

7.7m9.1m7.1m7.7m6.6m

Operating expense total

17.3m18.0m16.8m13.9m11.9m

EBIT

(17.2m)(19.1m)(16.6m)(13.8m)(11.4m)

EBIT margin, %

(11445%)(9695%)(12519%)(15004%)(2612%)

Interest expense

16.0k11.0k3.0k

Interest income

791.0k364.0k129.0k88.0k

Net Income

(16.2m)(17.4m)(15.2m)(7.5m)(8.3m)

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Revenue

36.0k76.0k36.0k45.0k36.0k47.0k23.0k39.0k15.0k22.0k84.0k213.0k90.0k56.0k33.0k38.0k

R&D expense

2.2m2.3m2.3m1.9m2.7m2.4m2.0m1.0m900.0k1.3m1.4m1.1m787.0k855.0k1.3m1.6m

General and administrative expense

2.1m2.5m2.5m2.2m1.9m2.0m1.7m2.4m1.6m1.6m1.7m1.6m1.6m1.6m1.7m1.3m

Operating expense total

4.5m5.2m5.1m4.4m4.6m4.9m4.0m3.7m2.8m3.2m3.3m2.9m2.7m2.6m3.3m3.1m

Depreciation and amortization

739.0k

EBIT

(4.5m)(5.1m)(5.1m)(4.3m)(4.9m)(4.9m)(4.0m)(3.7m)(2.8m)(3.2m)(3.2m)(2.7m)(2.7m)(2.6m)(3.2m)(3.0m)

EBIT margin, %

(12386%)(6726%)(14125%)(9620%)(13675%)(10428%)(17317%)(9433%)(18760%)(14664%)(3858%)(1282%)(2947%)(4589%)(9779%)(7995%)

Interest expense

4.0k3.0k3.0k3.0k2.0k1.0k

Interest income

89.0k153.0k131.0k130.0k61.0k26.0k4.0k51.0k10.0k

Net Income

(5.1m)(3.8m)(5.0m)(4.2m)(3.4m)(4.8m)(3.8m)(2.2m)(1.3m)(2.9m)(2.8m)(2.2m)(1.3m)(2.7m)(2.4m)(3.1m)

Hemispherx BioPharma Balance Sheet

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

803.0k2.2m2.1m2.4m1.4m

Accounts Receivable

24.0k

Inventories

399.0k335.0k

Current Assets

18.6m16.5m10.6m6.9m3.5m

PP&E

5.1m4.6m11.2m9.5m8.6m

Total Assets

31.9m29.4m22.8m18.9m14.2m

Accounts Payable

1.3m2.1m1.2m887.0k741.0k

Short-term debt

1.8m

Current Liabilities

2.5m4.4m2.4m2.4m2.7m

Long-term debt

Total Debt

1.8m

Total Liabilities

2.6m

Additional Paid-in Capital

289.6m302.7m313.2m316.0m317.4m

Retained Earnings

(260.3m)(277.8m)(293.0m)(300.5m)(308.8m)

Total Equity

20.4m15.5m8.7m

Debt to Equity Ratio

0.2 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.1 x1.2 x1.6 x

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Cash

1.6m4.1m2.6m1.3m2.9m1.8m1.2m1.0m1.5m4.5m776.0k1.2m503.0k4.0m3.6m4.1m

Accounts Receivable

41.0k98.0k42.0k29.0k35.0k28.0k

Inventories

626.0k

Current Assets

29.6m21.9m20.5m17.7m17.9m17.1m14.0m9.5m10.7m9.3m5.2m4.7m3.7m5.7m5.3m4.9m

PP&E

5.1m4.9m4.8m4.7m11.8m11.7m11.5m10.9m10.1m9.8m9.3m9.0m8.8m8.4m8.1m8.0m

Total Assets

42.9m35.0m33.5m30.6m30.8m29.9m26.5m21.5m21.9m21.6m16.9m16.1m14.7m16.3m15.7m15.2m

Accounts Payable

1.7m1.2m1.5m2.4m2.3m1.6m1.5m1.4m1.4m1.0m927.0k972.0k460.0k850.0k689.0k791.0k

Short-term debt

517.0k1.5m

Current Liabilities

10.6m3.0m4.2m4.3m3.8m3.1m3.3m3.1m4.4m2.4m2.6m2.7m2.2m2.7m2.1m5.0m

Total Debt

517.0k1.5m

Total Liabilities

10.7m3.0m4.2m4.3m

Additional Paid-in Capital

289.2m296.1m298.2m299.6m308.0m312.8m313.2m313.3m313.6m315.9m316.2m316.3m316.7m321.6m322.9m323.4m

Retained Earnings

(257.1m)(264.2m)(269.1m)(273.3m)(281.2m)(286.1m)(289.9m)(295.2m)(296.5m)(299.3m)(303.3m)(306.0m)(306.8m)(311.5m)(313.9m)(317.0m)

Total Equity

26.8m23.2m18.4m17.5m16.6m12.9m10.3m10.0m10.2m9.1m6.4m

Debt to Equity Ratio

0.1 x

Debt to Assets Ratio

0.1 x

Financial Leverage

1.1 x1.1 x1.2 x1.3 x1.3 x1.3 x1.6 x1.5 x1.6 x1.7 x2.4 x

Hemispherx BioPharma Cash Flow

Annual

USDFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(16.2m)(17.4m)(15.2m)(7.5m)(8.3m)

Depreciation and Amortization

671.0k665.0k941.0k1.1m948.0k

Accounts Receivable

(24.0k)

Inventories

(1.3m)

Accounts Payable

(617.0k)869.0k(196.0k)(326.0k)566.0k

Cash From Operating Activities

(16.8m)(13.9m)(16.1m)(7.4m)(7.9m)

Cash From Investing Activities

22.3m2.5m6.4m2.9m2.7m

Cash From Financing Activities

(6.8m)12.8m9.7m4.8m4.2m

Quarterly

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018

Net Income

(13.0m)(3.8m)(8.8m)(13.0m)(3.4m)(8.3m)(12.1m)(2.2m)(3.5m)(6.3m)(2.8m)(5.0m)(6.3m)(2.7m)(5.1m)(8.2m)

Depreciation and Amortization

504.0k167.0k332.0k500.0k180.0k458.0k663.0k300.0k576.0k854.0k261.0k504.0k739.0k216.0k444.0k658.0k

Accounts Receivable

(41.0k)(98.0k)(42.0k)(6.0k)(11.0k)(4.0k)

Inventories

453.0k(480.0k)(1.0m)(1.3m)

Accounts Payable

(197.0k)(16.0k)238.0k1.2m236.0k189.0k97.0k182.0k178.0k(202.0k)103.0k85.0k174.0k245.0k126.0k277.0k

Cash From Operating Activities

(13.6m)(2.9m)(6.2m)(9.9m)(4.3m)(9.2m)(12.7m)(1.0m)(2.3m)(5.3m)(3.0m)5.3m(7.2m)(2.5m)(5.2m)(8.2m)

Cash From Investing Activities

13.1m(177.0k)(420.0k)651.0k(192.0k)(355.0k)2.1m(60.0k)1.6m2.9m486.0k1.5m1.6m1.0m993.0k1.6m

Cash From Financing Activities

(36.0k)6.4m8.4m9.7m5.2m9.3m9.7m1.0k162.0k4.7m875.0k2.6m3.6m4.1m6.4m9.3m

Hemispherx BioPharma Ratios

USDY, 2018

Financial Leverage

2.4 x
Download Excel
Report incorrect company information

Hemispherx BioPharma Employee Rating

1.88 votes
Culture & Values
1.8
Work/Life Balance
1.6
Senior Management
1.6
Salary & Benefits
1.4
Career Opportunities
1.2
Source
View Hemispherx BioPharma profile

Competitors

Kiniksa Pharmaceuticals
Healthcare - Public
Sartorius Stedim BioOutsource
Healthcare - Subsidiary
Neurosearch
Healthcare - Public
Biogen
Healthcare - Public
Compare competitors